Amedisys (AMED) Stock Forecast, Price Target & Predictions
AMED Stock Forecast
Amedisys stock forecast is as follows: an average price target of $143.38 (represents a 55.37% upside from AMED’s last price of $92.28) and a rating consensus of 'Hold', based on 10 wall street analysts offering a 1-year stock forecast.
AMED Price Target
The average price target for Amedisys (AMED) is $143.38 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $190.00 to $85.00. This represents a potential 55.37% upside from AMED's last price of $92.28.
AMED Analyst Ratings
According to 10 Wall Street analysts, Amedisys's rating consensus is 'Hold'. The analyst rating breakdown for AMED stock is 0 'Strong Buy' (0.00%), 4 'Buy' (40.00%), 6 'Hold' (60.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Amedisys Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Mar 25, 2024 | Frank Morgan | RBC Capital | $100.00 | $92.16 | 8.51% | 8.37% |
| Jul 06, 2023 | Brian Tanquilut | Jefferies | $90.80 | $91.28 | -0.53% | -1.60% |
| Jan 05, 2023 | Leerink Partners | $85.00 | $86.00 | -1.16% | -7.89% | |
| Nov 11, 2022 | Stephens | $106.00 | $91.78 | 15.49% | 14.87% | |
| Jul 26, 2022 | David MacDonald | Truist Financial | $150.00 | $128.18 | 17.02% | 62.55% |
| Jul 03, 2022 | Justin Bowers | Deutsche Bank | $175.00 | $110.82 | 57.91% | 89.64% |
| Apr 29, 2022 | Credit Suisse | $182.00 | $131.13 | 38.80% | 97.23% | |
| Apr 29, 2022 | Raymond James | $180.00 | $128.41 | 40.18% | 95.06% | |
| Apr 29, 2022 | Leerink Partners | $131.00 | $131.89 | -0.67% | 41.96% | |
| Feb 25, 2022 | Matthew Borsch | BMO Capital | $190.00 | $159.90 | 18.82% | 105.90% |
| Feb 25, 2022 | Ben Hendrix | RBC Capital | $199.00 | $159.90 | 24.45% | 115.65% |
| Feb 24, 2022 | Justin Bowers | Deutsche Bank | $230.00 | $147.93 | 55.48% | 149.24% |
| Feb 24, 2022 | Bill Sutherland | Benchmark Co. | $175.00 | $147.93 | 18.30% | 89.64% |
| Nov 04, 2021 | Scott Fidel | Stephens | $185.00 | $174.01 | 6.32% | 100.48% |
The latest Amedisys stock forecast, released on Mar 25, 2024 by Frank Morgan from RBC Capital, set a price target of $100.00, which represents a 8.51% increase from the stock price at the time of the forecast ($92.16), and a 8.37% increase from AMED last price ($92.28).
Amedisys Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $100.00 |
| Last Closing Price | $92.28 | $92.28 | $92.28 |
| Upside/Downside | -100.00% | -100.00% | 8.37% |
In the current month, the average price target of Amedisys stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Amedisys's last price of $92.28. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 29, 2024 | Deutsche Bank | Buy | Hold | Downgrade |
| Jul 01, 2024 | William Blair | Market Perform | Downgrade | |
| Sep 14, 2023 | Cantor Fitzgerald | Neutral | Neutral | Hold |
| Jan 05, 2023 | SVB Leerink | Market Perform | Market Perform | Hold |
| Nov 11, 2022 | Stephens | Equal-Weight | Equal-Weight | Hold |
| Oct 27, 2022 | Raymond James | Outperform | Market Perform | Downgrade |
| Jul 03, 2022 | Deutsche Bank | Buy | Buy | Hold |
| Jun 21, 2022 | Stephens | Equal-Weight | Equal-Weight | Hold |
| Apr 29, 2022 | Credit Suisse | Outperform | Outperform | Hold |
| Apr 29, 2022 | Raymond James | Outperform | Outperform | Hold |
| Apr 29, 2022 | SVB Leerink | Market Perform | Market Perform | Hold |
| Feb 25, 2022 | Credit Suisse | Outperform | Outperform | Hold |
| Feb 25, 2022 | Oppenheimer | Outperform | Outperform | Hold |
| Feb 25, 2022 | BMO Capital | Outperform | Upgrade | |
| Feb 24, 2022 | Benchmark | Buy | Buy | Hold |
| Feb 18, 2022 | SVB Leerink | Market Perform | Market Perform | Hold |
Amedisys's last stock rating was published by Deutsche Bank on Jul 29, 2024. The company Downgrade its AMED rating from "Buy" to "Hold".
Amedisys Financial Forecast
Amedisys Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $556.24M | $552.97M | $556.39M | $562.06M | $557.99M | $557.89M | $545.26M | $559.32M | $553.49M | $564.17M | $537.14M | $550.71M | $544.07M | $485.06M | $491.69M | $500.68M | $494.63M |
| Avg Forecast | $672.55M | $668.90M | $661.85M | $653.58M | $630.09M | $620.66M | $617.68M | $600.00M | $597.51M | $586.75M | $578.79M | $565.38M | $567.40M | $560.23M | $568.18M | $558.96M | $560.56M | $579.31M | $583.12M | $558.82M | $555.18M | $568.27M | $565.48M | $542.50M | $553.34M | $533.67M | $468.41M | $504.84M | $511.58M | $494.23M |
| High Forecast | $720.15M | $716.24M | $708.69M | $699.83M | $674.68M | $664.58M | $661.39M | $603.91M | $603.28M | $587.77M | $579.44M | $565.38M | $575.06M | $567.85M | $608.39M | $598.51M | $588.10M | $579.31M | $583.12M | $558.82M | $555.18M | $568.27M | $565.48M | $542.50M | $553.34M | $533.67M | $468.41M | $504.84M | $511.58M | $494.23M |
| Low Forecast | $660.87M | $657.29M | $650.36M | $642.23M | $619.15M | $609.88M | $606.95M | $596.87M | $588.90M | $585.74M | $578.14M | $565.38M | $559.88M | $551.38M | $558.32M | $549.25M | $552.53M | $579.31M | $583.12M | $558.82M | $555.18M | $568.27M | $565.48M | $542.50M | $553.34M | $533.67M | $468.41M | $504.84M | $511.58M | $494.23M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 8 | 4 | 3 | 3 | 6 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 9 | 9 | 9 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.99% | 0.97% | 1.00% | 1.00% | 0.96% | 0.96% | 0.98% | 1.01% | 0.97% | 1.00% | 0.99% | 1.00% | 1.02% | 1.04% | 0.97% | 0.98% | 1.00% |
Amedisys's average Quarter revenue forecast for Dec 23 based on 6 analysts is $567.40M, with a low forecast of $559.88M, and a high forecast of $575.06M. AMED's average Quarter revenue forecast represents a 2.01% increase compared to the company's last Quarter revenue of $556.24M (Sep 23).
Amedisys EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 8 | 4 | 3 | 3 | 6 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 9 | 9 | 9 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $65.47M | $-65.01M | $56.54M | $63.59M | $60.59M | $67.25M | $65.01M | $69.03M | $76.43M | $127.20M | $87.26M | $82.81M | $83.34M | $63.29M | $58.77M | $56.99M | $61.71M |
| Avg Forecast | $75.34M | $74.93M | $74.14M | $73.21M | $70.58M | $69.53M | $69.19M | $67.21M | $66.93M | $65.73M | $64.84M | $70.89M | $63.56M | $62.76M | $63.65M | $64.44M | $75.94M | $72.57M | $73.05M | $58.59M | $69.55M | $71.19M | $70.84M | $80.55M | $69.32M | $66.85M | $58.68M | $53.93M | $64.08M | $61.91M |
| High Forecast | $80.67M | $80.23M | $79.39M | $78.39M | $75.58M | $74.45M | $74.09M | $67.65M | $67.58M | $65.84M | $64.91M | $85.07M | $64.42M | $63.61M | $68.15M | $77.33M | $91.12M | $72.57M | $73.05M | $70.30M | $69.55M | $71.19M | $70.84M | $96.66M | $69.32M | $66.85M | $58.68M | $64.71M | $64.08M | $61.91M |
| Low Forecast | $74.03M | $73.63M | $72.85M | $71.94M | $69.36M | $68.32M | $67.99M | $66.86M | $65.97M | $65.61M | $64.76M | $56.71M | $62.72M | $61.76M | $62.54M | $51.56M | $60.75M | $72.57M | $73.05M | $46.87M | $69.55M | $71.19M | $70.84M | $64.44M | $69.32M | $66.85M | $58.68M | $43.14M | $64.08M | $61.91M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | -1.02% | 0.88% | 0.84% | 0.83% | 0.92% | 1.11% | 0.99% | 1.07% | 1.80% | 1.08% | 1.19% | 1.25% | 1.08% | 1.09% | 0.89% | 1.00% |
6 analysts predict AMED's average Quarter EBITDA for Dec 23 to be $63.56M, with a high of $64.42M and a low of $62.72M. This is -2.91% lower than Amedisys's previous annual EBITDA (Sep 23) of $65.47M.
Amedisys Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 8 | 4 | 3 | 3 | 6 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 9 | 9 | 9 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $25.96M | $-43.98M | $25.25M | $31.72M | $25.64M | $29.58M | $31.67M | $34.01M | $45.01M | $80.15M | $49.87M | $45.15M | $71.98M | $34.67M | $31.80M | $27.66M | $34.13M |
| Avg Forecast | $41.09M | $40.59M | $47.55M | $40.76M | $38.77M | $38.73M | $46.39M | $37.07M | $34.97M | $39.54M | $39.26M | $34.56M | $34.19M | $35.74M | $36.18M | $31.42M | $37.45M | $40.23M | $40.65M | $28.56M | $38.88M | $45.14M | $55.04M | $46.03M | $48.53M | $41.93M | $26.87M | $29.18M | $30.60M | $29.58M |
| High Forecast | $44.87M | $44.32M | $51.92M | $44.51M | $42.33M | $42.29M | $50.66M | $40.50M | $36.29M | $39.85M | $39.30M | $41.47M | $40.43M | $43.68M | $37.84M | $37.70M | $44.94M | $41.13M | $41.89M | $34.27M | $38.88M | $47.14M | $55.04M | $55.24M | $48.53M | $41.93M | $26.87M | $35.01M | $30.60M | $29.58M |
| Low Forecast | $40.16M | $39.67M | $46.48M | $39.84M | $37.89M | $37.85M | $45.34M | $34.67M | $32.99M | $39.24M | $39.23M | $27.65M | $30.57M | $31.44M | $34.52M | $25.13M | $29.96M | $39.34M | $39.40M | $22.85M | $38.88M | $43.15M | $55.04M | $36.83M | $48.53M | $41.93M | $26.87M | $23.34M | $30.60M | $29.58M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.73% | -1.22% | 0.80% | 0.85% | 0.64% | 0.73% | 1.11% | 0.87% | 1.00% | 1.46% | 1.08% | 0.93% | 1.72% | 1.29% | 1.09% | 0.90% | 1.15% |
Amedisys's average Quarter net income forecast for Dec 23 is $34.19M, with a range of $30.57M to $40.43M. AMED's average Quarter net income forecast represents a 31.69% increase compared to the company's last Quarter net income of $25.96M (Sep 23).
Amedisys SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 8 | 4 | 3 | 3 | 6 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 9 | 9 | 9 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $192.98M | - | $194.56M | $193.43M | $188.34M | $187.82M | $184.47M | $184.85M | $178.93M | $175.22M | $172.24M | $175.60M | $179.62M | $156.34M | $156.74M | $156.06M | $154.71M |
| Avg Forecast | $220.96M | $219.76M | $217.44M | $214.73M | $207.01M | $203.91M | $202.93M | $197.12M | $196.30M | $192.77M | $190.15M | $201.28M | $186.41M | $184.06M | $186.67M | $182.98M | $203.34M | $151.26M | $152.26M | $166.35M | $144.96M | $148.38M | $147.65M | $158.99M | $144.48M | $139.35M | $122.31M | $143.81M | $133.58M | $129.05M |
| High Forecast | $236.59M | $235.31M | $232.83M | $229.92M | $221.66M | $218.34M | $217.29M | $198.41M | $198.20M | $193.10M | $190.37M | $241.54M | $188.93M | $186.56M | $199.88M | $219.58M | $244.00M | $151.26M | $152.26M | $199.62M | $144.96M | $148.38M | $147.65M | $190.79M | $144.48M | $139.35M | $122.31M | $172.58M | $133.58M | $129.05M |
| Low Forecast | $217.12M | $215.94M | $213.67M | $211.00M | $203.41M | $200.37M | $199.41M | $196.09M | $193.48M | $192.44M | $189.94M | $161.03M | $183.94M | $181.15M | $183.43M | $146.39M | $162.67M | $151.26M | $152.26M | $133.08M | $144.96M | $148.38M | $147.65M | $127.19M | $144.48M | $139.35M | $122.31M | $115.05M | $133.58M | $129.05M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.05% | - | 1.06% | 0.95% | 1.25% | 1.23% | 1.11% | 1.28% | 1.21% | 1.19% | 1.08% | 1.22% | 1.29% | 1.28% | 1.09% | 1.17% | 1.20% |
Amedisys's average Quarter SG&A projection for Dec 23 is $186.41M, based on 6 Wall Street analysts, with a range of $183.94M to $188.93M. The forecast indicates a -3.40% fall compared to AMED last annual SG&A of $192.98M (Sep 23).
Amedisys EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 8 | 4 | 3 | 3 | 6 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 9 | 9 | 9 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.80 | $-1.35 | $0.78 | $0.98 | $0.79 | $0.91 | $0.97 | $1.04 | $1.38 | $2.46 | $1.52 | $1.38 | $2.20 | $1.07 | $0.98 | $0.86 | $1.06 |
| Avg Forecast | $1.24 | $1.23 | $1.44 | $1.23 | $1.17 | $1.17 | $1.40 | $1.12 | $1.06 | $1.19 | $1.19 | $1.02 | $1.03 | $1.08 | $1.09 | $0.88 | $0.97 | $1.22 | $1.23 | $1.12 | $1.18 | $1.37 | $1.67 | $1.43 | $1.47 | $1.27 | $0.81 | $0.97 | $0.93 | $0.90 |
| High Forecast | $1.35 | $1.34 | $1.57 | $1.34 | $1.28 | $1.28 | $1.53 | $1.22 | $1.10 | $1.20 | $1.19 | $1.02 | $1.22 | $1.32 | $1.14 | $0.97 | $1.03 | $1.24 | $1.27 | $1.12 | $1.18 | $1.43 | $1.67 | $1.43 | $1.47 | $1.27 | $0.81 | $0.97 | $0.93 | $0.90 |
| Low Forecast | $1.21 | $1.20 | $1.40 | $1.20 | $1.14 | $1.14 | $1.37 | $1.05 | $1.00 | $1.18 | $1.18 | $1.02 | $0.92 | $0.95 | $1.04 | $0.86 | $0.95 | $1.19 | $1.19 | $1.12 | $1.18 | $1.31 | $1.67 | $1.43 | $1.47 | $1.27 | $0.81 | $0.97 | $0.93 | $0.90 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.74% | -1.24% | 0.88% | 1.01% | 0.65% | 0.74% | 0.87% | 0.88% | 1.01% | 1.48% | 1.07% | 0.94% | 1.73% | 1.32% | 1.01% | 0.93% | 1.18% |
According to 6 Wall Street analysts, Amedisys's projected average Quarter EPS for Dec 23 is $1.03, with a low estimate of $0.92 and a high estimate of $1.22. This represents a 28.97% increase compared to AMED previous annual EPS of $0.80 (Sep 23).
Amedisys Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ACHC | Acadia Healthcare | $43.74 | $81.50 | 86.33% | Buy |
| INNV | InnovAge | $3.73 | $6.80 | 82.31% | Hold |
| AMED | Amedisys | $92.28 | $143.38 | 55.37% | Hold |
| HCSG | Healthcare Services Group | $11.36 | $17.33 | 52.55% | Hold |
| UHS | Universal Health Services | $187.18 | $274.00 | 46.38% | Hold |
| SGRY | Surgery Partners | $25.75 | $36.33 | 41.09% | Buy |
| PNTG | Pennant Group | $27.51 | $34.67 | 26.03% | Buy |
| ENSG | Ensign Group | $140.58 | $167.33 | 19.03% | Buy |
| ADUS | Addus HomeCare | $126.27 | $146.20 | 15.78% | Buy |
| EHAB | Enhabit | $8.40 | $9.50 | 13.10% | Hold |
| EHC | Encompass Health | $95.57 | $107.50 | 12.48% | Buy |
| OPCH | Option Care Health | $30.95 | $30.33 | -2.00% | Buy |